Tianyan Zhou

school of pharmaceutical sciences

H指数:25

被引数:2,460

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Pharmacokinetic/pharmacodynamic modeling of therapeutic antibodies in oncology: current advances and future perspectives

肿瘤学中治疗性抗体的药代动力学/药效动力学建模：当前进展与未来展望

Journal of Pharmaceutical Investigation

IF5.1

2025-10-290

PRE

PK/PD modeling of the effect of Escitalopram combined with Docetaxel in the treatment of breast cancer with depression in mice

小鼠抑郁性乳腺癌治疗中艾司西酞普兰联合多西他赛效应的药代动力学/药效学建模

Journal of Pharmaceutical Sciences

IF3.8

2025-09-160

PRE

Prognostic implications of antitumour efficacy and adverse events of EGFR-TKIs in non-small cell lung cancer: an ambispective cohort study

EGFR-TKIs在非小细胞肺癌中的抗肿瘤疗效和不良反应的预后意义：一项双向队列研究

European Journal of Pharmacology

IF4.7

2025-09-150

PRE

Population Pharmacokinetics and Exposure-Response Relationship of Hemoporfin in Pediatric Patients With Port-Wine Stain

血卟啉素在葡萄酒色斑患儿的群体药代动力学及暴露-反应关系

cpt pharmacometrics systems pharmacology

IF0

2025-05-300

OAAI

Longitudinal and time-to-event modeling for the survival of advanced pancreatic ductal adenocarcinoma patients

ACTA PHARMACOLOGICA SINICA

IF8.4

2024-10-210

PRE

Population PK/PD model of tacrolimus for exploring the relationship between accumulated exposure and quantitative scores in myasthenia gravis patients

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2023-04-212

OAAI

A model-based meta-analysis of immune-related adverse events during immune checkpoint inhibitors treatment for NSCLC

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2022-07-042

OAAI

Longitudinal and time-to-event modeling for prognostic implications of radical surgery in retroperitoneal sarcoma

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2022-07-043

QAP14 suppresses stemness and metastasis of breast cancer via the activation of dopamine D1 receptor (vol 0, pg 1, 2022)

ACTA PHARMACOLOGICA SINICA

IF8.4

2022-01-261

QAP14 suppresses breast cancer stemness and metastasis via activation of dopamine D1 receptor

QAP14通过激活多巴胺D1受体抑制乳腺癌的干和转移

ACTA PHARMACOLOGICA SINICA

IF8.4

2021-06-288

OAAI

Mechanistic prediction of first-in-human dose for bispecific CD3/EpCAM T-cell engager antibody M701, using an integrated PK/PD modeling method

使用集成的PK/PD建模方法对双特异性CD3/EpCAM T细胞接合器抗体M701的首次人体剂量进行机理预测

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

IF4.7

2021-03-0112

PREAI

Concordance of genomic alterations by next-generation sequencing in tumour tissue versus circulating tumour DNA in urothelial carcinoma

ANNALS OF ONCOLOGY

IF65.4

2020-11-010

OAAI

Important roles of estrogen receptor alpha in tumor progression and anti-estrogen therapy of pancreatic ductal adenocarcinoma

LIFE SCIENCES

IF5.1

2020-11-018

PREAI

Prediction of Human Pharmacokinetics and Clinical Effective Dose of SI-B001, an EGFR/HER3 Bi-specific Monoclonal Antibody

JOURNAL OF PHARMACEUTICAL SCIENCES

IF3.8

2020-10-0117

OAAI

Development and validation of a highly sensitive HPLC-MS/MS method for the QAP14, a novel potential anti-cancer agent, in rat plasma and its application to a pharmacokinetic study

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

IF3.1

2020-09-016

PREAI

Dexamethasone inhibits pancreatic tumor growth in preclinical models: Involvement of activating glucocorticoid receptor

TOXICOLOGY AND APPLIED PHARMACOLOGY

IF3.4

2020-08-0121

PREAI

Pharmacokinetic/Pharmacodynamic Modeling of the Anti-Cancer Effect of Dexamethasone in Pancreatic Cancer Xenografts and Anticipation of Human Efficacious Doses

JOURNAL OF PHARMACEUTICAL SCIENCES

IF3.8

2020-02-016

PREAI

Development and validation of a LC-MS/MS method for simultaneous determination of six glucocorticoids and its application to a pharmacokinetic study in nude mice

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

IF3.1

2020-02-0115

PREAI

N-arylpiperazine-containing compound (C2): An enhancer of sunitinib in the treatment of pancreatic cancer, involving D1DR activation

TOXICOLOGY AND APPLIED PHARMACOLOGY

IF3.4

2019-12-0112

PREAI

Dopamine D1 receptor agonists inhibit lung metastasis of breast cancer reducing cancer sternness

EUROPEAN JOURNAL OF PHARMACOLOGY

IF4.7

2019-09-0127

PREAI

Tianyan Zhou

个人简介

教育背景

工作经历

荣誉奖项

研究方向